The challenge of drug resistance in cancer treatment: a current overview

M Nikolaou, A Pavlopoulou, AG Georgakilas… - Clinical & Experimental …, 2018 - Springer
It is generally accepted that recent advances in anticancer agents have contributed
significantly to the improvement of both the disease-free survival and quality of life in cancer …

The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents

EK Rowinsky, MD - Annual review of medicine, 1997 - annualreviews.org
▪ Abstract The taxane class of antimicrotubule anticancer agents is perhaps the most
important addition to the chemotherapeutic armamentarium against cancer over the past …

Microtubules and actin filaments: dynamic targets for cancer chemotherapy

MA Jordan, L Wilson - Current opinion in cell biology, 1998 - Elsevier
Microtubules and actin filaments play important roles in mitosis, cell signaling, and motility.
Thus these cytoskeletal filaments are the targets of a growing number of anti-cancer drugs …

Paclitaxel-resistant human ovarian cancer cells have mutant β-tubulins that exhibit impaired paclitaxel-driven polymerization

P Giannakakou, DL Sackett, YK Kang, Z Zhan… - Journal of Biological …, 1997 - ASBMB
Acquired resistance to paclitaxel can be mediated by P-glycoprotein or by alterations
involving tubulin. We report two paclitaxel-resistant sublines derived from 1A9 human …

Multiple forms of tubulin: different gene products and covalent modifications

RF Ludueña - International review of cytology, 1997 - Elsevier
Tubulin, the subunit protein of microtubules, is an α/β heterodimer. In many organisms, both
α and β exist in numerous isotypic forms encoded by different genes. In addition, both α and …

Microtubule-targeted anticancer agents and apoptosis

KN Bhalla - Oncogene, 2003 - nature.com
Over the past decade, significant progress has been made in our understanding of the
biology of microtubule (MT) assembly into the mitotic spindle during mitosis and the …

Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation

RZ Yusuf, Z Duan, DE Lamendola… - Current cancer drug …, 2003 - ingentaconnect.com
It has been approximately ten years since the Food and Drug Administration (FDA)
approved paclitaxel for the treatment of platinum resistant epithelial ovarian carcinoma …

Microtubule structure at 8 Å resolution

H Li, DJ DeRosier, WV Nicholson, E Nogales… - Structure, 2002 - cell.com
We have obtained a 3D reconstruction of intact microtubules, using cryoelectron microscopy
and image processing, at a resolution of about 8 Å, sufficient to resolve much of the …

[HTML][HTML] Results of a multicenter phase II trial of brentuximab vedotin as second-line therapy before autologous transplantation in relapsed/refractory Hodgkin …

R Chen, JM Palmer, P Martin, N Tsai, Y Kim… - Biology of blood and …, 2015 - Elsevier
This multicenter prospective phase II study examines the activity and tolerability of
brentuximab vedotin as second-line therapy in patients with Hodgkin lymphoma that was …

Molecular pathways: regulation and therapeutic implications of multidrug resistance

KG Chen, BI Sikic - Clinical cancer research, 2012 - AACR
Multidrug transporters constitute major mechanisms of MDR in human cancers. The ABCB1
(MDR1) gene encodes a well-characterized transmembrane transporter, termed P …